October 22nd 2024
The acquisition creates a clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations.
SalioGen Therapeutics taps development candidate for ABCA4-mediated Stargardt disease
April 19th 2024According to the company, SGT-1001 uses its novel gene coding technology for gene integration via transposition. It plans to advance SGT-1001 into the clinic in the first half of 2025. Preclinical data for SGT-1001 will be presented at the Association for Research in Vision and Ophthalmology and the American Society of Gene & Cell Therapy annual meetings.
Ocugen, Inc. announces FDA clearance of IND amendment to Initiate OCU400 Phase 3 clinical trial
April 8th 2024According to the company, the Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the other arm with 75 participants that are gene agnostic.